Reason for request
Reassessment
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of BLENREP (belantamab mafodotin) 100 mg, powder for solution for dilution for infusion, is insufficient in the MA indication to justify public funding. |
Clinical Added Value
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
YUUHbs5Zy3DZRDac
